Anna López-Ferrer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Objectives To assess the impact of chronic inflammatory burden on the risk of aortic valve outcomes and atrioventricular block (AVB) in SpA. Methods Ambispective cohort study of 461 SpA patients meeting ASAS criteria between September 2022 and April 2024. Chronic inflammation burden was measured by symptom duration, number of DMARDs discontinued due to inefficacy and total exposure to persistent inflammation. Statistical analysis was performed with multiple time-dependent Cox regression, maintaining a variable-to-event ratio. Results Disease duration, especially from initial musculoskeletal (MSK) symptoms, affected all outcomes. Every five-year increase in symptom duration raised the risk of aortic regurgitation (HR 1.21, 95% CI 1.06–1.37), valve sclerosis (HR 1.07, 95% CI 1.02–1.12), root dilation (HR 1.31, 95% CI 1.08–1.59) and AVB (HR 1.34, 95% CI 1.05–1.71). Age also increased risks, particularly for aortic regurgitation (HR 1.46 per decade) and valve sclerosis (HR 1.74 per decade). Surprisingly, hypertension showed a consistent protective effect, decreasing the risk for aortic root dilation (HR 0.55, 95% CI 0.36–0.84), valve sclerosis (HR 0.62, 95% CI 0.40–0.96) and aortic regurgitation (HR 0.60, 95% CI 0.37–0.98). Peripheral SpA significantly predicted aortic valve sclerosis (HR 1.95, 95% CI 1.13–3.36), and enthesitis strongly influenced AVB risk (HR 3.04, 95% CI 1.24–7.44). Conclusions The duration of MSK symptoms more strongly predicted all outcomes than extra-MSK symptoms. Age’s impact mirrored general population trends. Surprisingly, hypertension protected against aortic conditions, prompting further research into IL-17 therapies. Peripheral SpA significantly predicted aortic valve sclerosis, and enthesitis strongly predicted AVB.
Year:
2026
Year:
2026
Psoriasis is a chronic inflammatory skin disease driven by genetic, environmental, and immune factors. While biologics like adalimumab (anti-TNFα) and risankizumab (anti-IL-23) have improved outcomes, patient response variability remains unclear. This study examined immune-related transcriptomic differences between lesional (L) and non-lesional (NL) psoriatic skin, focusing on immune-related hub genes, their plasma levels, and their correlations with severity and treatment response. Patients with moderate-to-severe psoriasis were enrolled before treatment with anti-TNFα (n = 16) or anti-IL-23 (n = 18). Plasma and paired L and NL skin biopsies were collected for RNA sequencing. Gene ontology enrichment analysis found four immune-related terms enriched in L skin: T-helper 17, granulocyte and lymphocyte chemotaxis, and antimicrobial humoral response. A protein–protein interaction network identified ten immune-related hub genes upregulated in L skin that correlated with clinical severity. Patients with prior treatments expressed distinctive gene profiles. Plasma levels of CCL20 strongly correlated with disease severity. Decision tree models identified CCL20 expression in skin and plasma levels of IL-6 and CXCL8 as candidate predictors for anti-TNFα response. Similarly, skin expression of CXCL8, IL-6, and CXCL10, alongside plasma levels of CCL20, IL-6, and CXCL8, may predict anti-IL-23 response. Ten immune-related hubs may serve as possible biomarkers for disease severity and therapeutic response in psoriasis.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Collaborators (8)
Sergio Santos Alarcón
-
Luis Puig
University of Barcelona
Albert Guinart Cuadra
Institut de Recerca Sant Pau
Hèctor Corominas
Professor titular / Professor Tenure track position
Universitat Autònoma de Barcelona (UAB)
Silvia Vidal
Associate professor
University of Barcelona
jose-manuel carrascosa
head of department, associated professor
Hospital Universitari Germans Trias i Pujol
anthony bewley
Honorary Professor
Queen Mary University of London
Marta Gut
Head of Sequencing Unit
Centro Nacional de Análisis Genómico (CNAG)
Make your next move.
Prepare your application
Review drafts before you send them.